Novartis AG ( / NVS ) remains a core consideration for healthcare-focused investors in 2026, balancing a 3.24% dividend yield against significant generic competition for its blockbuster drugs. While the company recently reported a 5% decline in Q1 sales due to patent expirations, management has reaffirmed its 2026 guidance , projecting a rebound in the second half of the year. Novartis AG (NOVN) CHF 108.50 5.14% since Jan 5, 2026 As of Apr 27, 18:30 GMT+3 • Disclaimer Apr 27, 2026 Open113.52 Mkt cap$291.76B USD 52-wk high131.00 High114.30 P/E ratio20.33 52-wk low87.89 Div yield3.24% Investment Thesis: Why Buy Novartis?
Should You Buy Novartis Stock Before October 28? - Yahoo Finance buy novartis stock
Acheteurs
Trouvez vos prestataires Faites votre demande, puis laissez nos équipes trouver pour vous les meilleures offres disponibles.Fournisseurs
Trouvez vos futurs clients Référencez vos produits et services pour améliorer votre présence sur le web et obtenez des demandes qualifiées.